NCT00427544View on ClinicalTrials.gov

Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

February 28, 2007

Study Completion Date

August 31, 2007

Conditions

Fibroid

Interventions

DRUG

PRA-027

Trial Locations (1)

33126

Miami

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00427544 - Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential | Biotech Hunter | Biotech Hunter